Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care

Recommendation ID: MTG65/01
Question: Further research is recommended to identify any health conditions or groups of patients that would benefit more from inhaled sedation with Sedaconda ACD-S than from standard care
Any explanatory notes (if applicable): The committee recognised that Sedaconda ACD-S is an efficient and safe way of delivering volatile anaesthetics in intensive care units. It noted that, although there is clear evidence that inhaled sedation using Sedaconda ACD-S can lead to faster wake-up time, the evidence around the decrease in length of stay in intensive care and time on mechanical ventilation are more difficult to understand because of the complexity of the underlying conditions of people in the intensive care unit. The committee concluded that further research is needed to address uncertainties in the appropriate population where Sedaconda ACD-S would be recommended for use compared with standard care.

Source guidance details

Comes from guidance: Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care
Number: MTG65
Date issued: January 2022

Is this a recommendation for the use of a technology only in the context of research?	No
Is it a recommendation that suggests collection of data or the establishment of a register?	No
Last Reviewed	31/01/2022